17 articles for JJ Court
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
31
Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2.
Vertex Pharmaceuticals
18
2,6-Disubstituted aryl carboxylic acids, leaving groups"par excellence" for benzisothiazolone inhibitors of human leukocyte elastase.
Sterling Winthrop Pharmaceutical Research Division
13
A comparative SAR and computer modeling study of benzisothiazolone, mechanism-based inhibitors with porcine pancreatic and human leukocyte elastase
TBA
19
A benzisothiazolone class of potent, selective mechanism-based inhibitors of human leukocyte elastase
TBA
4
Discovery of Novel Allosteric HCV NS5B Inhibitors. 2. Lactam-Containing Thiophene Carboxylates.
Vertex Pharmaceuticals
50
Discovery and Optimization of Pyrazole Amides as Inhibitors of ELOVL1.
Vertex Pharmaceuticals
27
Discovery of Novel, Orally Bioavailable Pyrimidine Ether-Based Inhibitors of ELOVL1.
Vertex Pharmaceuticals
17
Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variants.
Vertex Pharmaceuticals
36
Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.
Vertex Pharmaceuticals
20
Discovery of Novel Thiophene-Based, Thumb Pocket 2 Allosteric Inhibitors of the Hepatitis C NS5B Polymerase with Improved Potency and Physicochemical Profiles.
Vertex Pharmaceuticals
8
Design and synthesis of novel conformationally restricted HIV protease inhibitors.
Vertex Pharmaceuticals
32
Design, synthesis, and conformational analysis of a novel series of HIV protease inhibitors.
Vertex Pharmaceuticals
8
Orally bioavailable benzisothiazolone inhibitors of human leukocyte elastase.
Sterling Winthrop
31
A novel class of cyclic beta-dicarbonyl leaving groups and their use in the design of benzisothiazolone human leukocyte elastase inhibitors.
Sterling Winthrop Pharmaceuticals Research Division